The IFN signature promoted impaired endothelial progenitor function which was successfully reversed by a type I IFN receptor-neutralizing antibody [18], underlying the need for a further investigation of IFN inhibition to prevent vascular damage in APS. The gene discussed is IFNA1; the disease is autoimmune polyendocrinopathy.